LEPR and breast cancer: As seen earlier for this peptide with glioblastoma and BC cells (Otvos et al., 2011a) and for leptin receptor (ObR) antagonists (Beccari et al., 2013) at high dose (10 μM) the pharmacological effects were reversed, and ADP355 inhibited CML cell growth to a smaller extent (Figure 1).